INHIBRX, INC.

INBX
Delayed Nasdaq - 01:00 2022-11-25 pm EST
30.33 USD +3.02%

Turn to zoom
Prev.30.33000000
Open29.05000000
High30.48000000
Low29.05000000
Volume98 258
Latest news
5d ago
11/18
11/18
11/16
Chart INHIBRX, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBullishNeutral
Resistance33,333,344,5
Spread/Res.-9,0%-9,0%-32%
Spread/Supp.5,3%91%234%
Support28,815,99,08
Financials
Sales 2022 2,60 M - -
Net income 2022 -139 M - -
Net cash 2022 77,0 M - -
P/E ratio 2022 -9,02x
Yield 2022 -
Capitalization 1 321 M 1 321 M -
EV / Sales 2022 478x
EV / Sales 2023 216x
Nbr of Employees 109
Free-Float 71,8%
Company
Inhibrx, Inc. is a clinical-stage biotechnology company focused on developing a pipeline of biologic therapeutic candidates. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological...
Sector :
Bio Therapeutic Drugs
Calendar :
2022-11-30 Presentation
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 30,33 $
Average target price 47,50 $
Spread / Average Target 56,6%